je.st
news
Tag: therapeutics
Opexa Therapeutics Inc (OPXA) Upgraded to "Buy" by Zacks Investment Research
2016-01-25 01:16:11| Biotech - Topix.net
The firm presently has a $2.00 price target on the biopharmaceutical company's stock. Zacks Investment Research 's target price indicates a potential upside of 4.04% from the stock's current price.
Tags: buy
research
investment
upgraded
Astellas Pharma $8.50 Tender Offer For Ocata Therapeutics Offer Fails Again
2016-01-22 20:04:29| Biotech - Topix.net
The ongoing battle for control of Ocata Therapeutics inched closer to completion today as an SEC filing reveals that 47% of outstanding shares have been tendered in response to the November 19, 2015 tender offer by Japan based Astellas Pharma to acquire the stem cell therapeutics company. This is the second extended tender deadline that has failed to achieve the required 50.1% shares despite an aggressive campaign by Ocata management to convince shareholders that the $360,000,000 tender offer is in the best interest of shareholders.
Tags: offer
fails
tender
pharma
Joseph Podolski Purchases 11,677 Shares of Repros Therapeutics Inc (RPRX) Stock
2016-01-08 09:17:58| Biotech - Topix.net
Repros Therapeutics Inc CEO Joseph Podolski purchased 11,677 shares of the firm's stock in a transaction that occurred on Thursday, January 7th. The shares were bought at an average price of $1.18 per share, for a total transaction of $13,778.86.
Tags: stock
joseph
shares
purchases
Esperion Therapeutics: Too Much Uncertainty To Go Long
2016-01-06 04:42:35| Biotech - Topix.net
I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions.
Tags: long
uncertainty
therapeutics
The Resignation Of Osiris Therapeutics' Auditor Really Opens The Door For More Accounting Concerns
2015-12-18 22:26:04| Biotech - Topix.net
OSIR has had issues surrounding revenue recognition and internal controls over financial reporting, and this auditor resignation does nothing to suggest that these issues are over. OSIR has had problems collecting on its accounts receivable balance, and has had negative operating cash flow despite positive net income.
Tags: door
accounting
concerns
opens
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »